Nitrogen Plasma or CO2? A resurfacing and remodelling decision that starts with your patient, not the device

Plasma or CO2, both powerful modalities. For a dermal clinician, power is not where the decision starts. Two questions come first: which resurfacing outcome can you deliver whilst lowering risk profiles, and which one can your patient plan around? Start there, and Nitrogen plasma or CO2 stops being the hard part.

Two shifts are colliding

Patients are shifting their spend toward regenerative and preventative treatments that build long-term skin function instead of quick fixes. Resurfacing fits squarely in that category. At the same time, there are more aesthetic claims to weigh than ever, making it harder to tell genuine fit from good marketing.

A recent survey* of aesthetic treatments found that patients’ trust in their practitioner is now the biggest reason they return, ahead of cost and convenience. In a saturated market, transparency sets a clinic apart and starts with honestly comparing options in front of a patient. A device decision made on hype rather than fit is the quickest way to lose someone who came to you because they were tired of being sold to.

Risk management is the first filter

As a dermal clinician, do you want to rely on prophylaxis and medical oversight to manage your patients? It’s this question that reshapes the CO2 conversation. 

The fully ablative CO2 pathway, which delivers dramatic single-session correction, may require antiviral or antibiotic prophylaxis to prevent infections or reactivation of the herpes simplex virus. It may also require anaesthesia beyond an over-the-counter topical.

In a clinic with a prescriber on the floor, that pathway is manageable and mitigates some risk. Working solo or in a dermal-led room without a prescriber does not. That gap is exactly where nitrogen plasma was built to sit. This modality lets you achieve a resurfacing and remodelling outcome without the prescription-gated parts that an aggressive CO2 protocol depends on.

What nitrogen plasma does

It helps to be precise here, because “plasma” covers very different technologies. Nitrogen plasma, the technology behind NeoGen, uses ultra-high radiofrequency to ionise medical-grade nitrogen into plasma, delivering controlled thermal energy to the epidermis and dermis simultaneously. 

That is a different mechanism from RF microplasma or handheld plasma pens, which arc energy into the skin in a fractional or spot-by-spot pattern and ablate as they go.

Nitrogen plasma treatments aren’t chromophore-dependent, so their results don’t hinge on how much water or pigment sits in the skin the way a laser does. Two clinical consequences follow.

First, it behaves consistently across Fitzpatrick I to VI, where non-fractional CO2 narrows to lighter skin due to hyperpigmentation risk. Second, the epidermis stays intact during treatment. It insulates during the pass, and the treated skin sheds on its own timeline instead of leaving an open wound. That intact barrier is why infection considerations that dictate a CO2 protocol differ here.

How deep it goes is your call, set by the energy you choose. Turn it up for a single corrective treatment. It reaches the reticular dermis and provides correction close to ablative resurfacing, with three to five days of shedding. Turn it down and trade some depth for one to two days of recovery. 

Where CO2 is required

Plasma does not suit every case. For some types of scarring on Fitzpatrick I to III, a fractional CO2 column reaches a targeted depth that plasma cannot match. 

For severe photoaging and the deepest perioral and periorbital lines and wrinkles, fully ablative CO2 still produces the most significant single-treatment change, and some patients will accept two to three weeks of recovery to achieve it.

If your clinic has a prescriber and the patient’s skin type and downtime tolerance align, then CO2 may be the right tool. The goal is the right outcome for the patient, not the newest device in the room.

The downtime conversation 

Compared to fully ablative CO2 and its two to three weeks of recovery, nitrogen plasma has much shorter downtime. Even so, a corrective treatment asks the patient to plan around three to five days of visible shedding, and that planning is where clinics hesitate.

That is not a clinical flaw. It is a question of scheduling and setting expectations, one you can plan for. The work sits on the marketing side rather than the device side, which puts it well within your control.

Clinics getting results from plasma treatments have integrated planning as part of their protocol. They discuss their patient’s capacity for downtime on certain days of the week to ensure it aligns with their work and social commitments. They also set these expectations before the deposit rather than after.

For patients who can’t take much time off, clinics use low-energy settings. When someone wants zero recovery, they recommend a different treatment pathway rather than pushing plasma where it doesn’t fit. That honesty earns the booking on the treatment that does.

So, plasma or CO2?

Run the decision through three filters in order. 

1. Risk management: Does the outcome you’re after require prescription medications? Do you need medical oversight?
2. Your patient’s skin: Will your patient’s Fitzpatrick type tolerate CO2, or do you need something that holds up across the range?
3. Your patient’s downtime: Can they plan for three to five days, or do they have none to give?

For many dermal clinicians, those three filters point to nitrogen plasma more often than CO2, it offers powerful results but delivers a customisable resurfacing outcome on a recovery patients can plan around.

Talk it through with our team

Whether you’re weighing up your resurfacing options or looking at bringing nitrogen plasma into your clinic, the useful next step is a conversation. Chat to the Laseraid team about NeoGen: where it fits your business, your patients, and your calendar, and where it doesn’t. Book a demo today.